HK Stock Market Move | HANSOH PHARMA(03692) rises over 3% as almonertinib resubmits EU marketing authorization application and receives EMA confirmation of acceptance

HANSOH PHARMA (03692) rose over 3%, up 3.27% as of press time, at HK$31.58, with a turnover of HK$89.7682 million. On the news front, HANSOH PHARMA announced that on September 29, 2026, the Group resubmitted the marketing authorization application (MAA) in the European Union for its innovative drug almonertinib to the European Medicines Agency (EMA), and on October 7, 2026, the EMA confirmed acceptance of the new MAA and officially initiated the centralized review procedure. The indications are: first-line treatment for adult patients with advanced non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 (L858R) substitution mutations, and treatment for adult patients with advanced NSCLC positive for the EGFR T790M mutation.